^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TMB-H + PD-L1 expression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Entrez ID:
    29126
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    4years
    Successful response to monotherapy of immune checkpoint inhibitor in intrahepatic cholangiocarcinoma with high tumor mutational burden and PD-L1 expression. (PubMed, Clin Res Hepatol Gastroenterol)
    No abstract available
    Journal • Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression • TMB-H • TMB-H + PD-L1 expression • TMB + PD-L1 expression
    over4years
    [VIRTUAL] Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer (NSCLC) patients with EGFR or HER2 exon 20 insertions. (ASCO 2020)
    NSCLC patients with EGFR/HER2 Ex20ins had distinct immune features. Patients with EGFR Ex20ins had significantly higher PD-L1 expression than those with HER2 mutations, which may be the underlying reason for the different responses to PD-1/PD-L1 blockage. Research Funding: None
    Clinical • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression • HER-2 mutation • HER-2 expression • EGFR exon 20 insertion • EGFR expression • HER-2 exon 20 insertion • TMB-H + PD-L1 expression • EGFR exon 20 mutation